Decreased Self-reported Physical Fitness Following SARS-CoV-2 Infection and the Impact of Vaccine Boosters in a Cohort Study

The long-term effects of coronavirus disease 2019 (COVID-19) on physical fitness are unclear, and the impact of vaccination on that relationship is uncertain. We compared survey responses in a 1-year study of US military service members with (n = 1923) and without (n = 1591) a history of severe acut...

Full description

Saved in:
Bibliographic Details
Published inOpen forum infectious diseases Vol. 10; no. 12; p. ofad579
Main Authors Richard, Stephanie A, Scher, Ann I, Rusiecki, Jennifer, Byrne, Celia, Berjohn, Catherine M, Fries, Anthony C, Lalani, Tahaniyat, Smith, Alfred G, Mody, Rupal M, Ganesan, Anuradha, Huprikar, Nikhil, Colombo, Rhonda E, Colombo, Christopher J, Schofield, Christina, Lindholm, David A, Mende, Katrin, Morris, Michael J, Jones, Milissa U, Flanagan, Ryan, Larson, Derek T, Ewers, Evan C, Bazan, Samantha E, Saunders, David, Maves, Ryan C, Livezey, Jeffrey, Maldonado, Carlos J, Edwards, Margaret Sanchez, Rozman, Julia S, O'Connell, Robert J, Simons, Mark P, Tribble, David R, Agan, Brian K, Burgess, Timothy H, Pollett, Simon D
Format Journal Article
LanguageEnglish
Published United States Oxford University Press 01.12.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The long-term effects of coronavirus disease 2019 (COVID-19) on physical fitness are unclear, and the impact of vaccination on that relationship is uncertain. We compared survey responses in a 1-year study of US military service members with (n = 1923) and without (n = 1591) a history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We fit Poisson regression models to estimate the association between history of SARS-CoV-2 infection and fitness impairment, adjusting for time since infection, demographics, and baseline health. The participants in this analysis were primarily young adults aged 18-39 years (75%), and 71.5% were male. Participants with a history of SARS-CoV-2 infection were more likely to report difficulty exercising (38.7% vs 18.4%; < .01), difficulty performing daily activities (30.4% vs 12.7%; < .01), and decreased fitness test (FT) scores (42.7% vs 26.2%; < .01) than those without a history of infection. SARS-CoV-2-infected participants were at higher risk of these outcomes after adjusting for other factors (unvaccinated: exercising: adjusted risk ratio [aRR], 3.99; 95% CI, 3.36-4.73; activities: aRR, 5.02; 95% CI, 4.09-6.16; FT affected: aRR, 2.55; 95% CI, 2.19-2.98). Among SARS-CoV-2-positive participants, full vaccination before infection was associated with a lower risk of post-COVID-19 fitness impairment (fully vaccinated: exercise: aRR, 0.81; 95% CI, 0.70-0.95; activities: aRR, 0.76; 95% CI, 0.64-0.91; FT: aRR, 0.87; 95% CI, 0.76-1.00; boosted: exercise: aRR, 0.62; 95% CI, 0.51-0.74; activities: aRR, 0.52; 95% CI, 0.41-0.65; FT: aRR, 0.59; 95% CI, 0.49-0.70). In this study of generally young, healthy military service members, SARS-CoV-2 infection was associated with lower self-reported fitness and exercise capacity; vaccination and boosting were associated with lower risk of self-reported fitness loss.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Potential conflicts of interest.  1045 S.D.P., T.H.B., J.S.R., and M.P.S. report that the Uniformed Services University (USU) Infectious Diseases Clinical Research Program (IDCRP), a US Department of Defense institution, and the HJF were funded under a Cooperative Research and Development Agreement to conduct an unrelated phase III COVID-19 monoclonal antibody immunoprophylaxis trial sponsored by AstraZeneca. The HJF, in support of the USU IDCRP, was funded by the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense to augment the conduct of an unrelated phase III vaccine trial sponsored by AstraZeneca. Both trials were part of the US Government COVID-19 response. Neither is related to the work presented here. R.C.M. receives research support paid to his institution from Sound Pharmaceuticals for an investigational COVID-19 therapeutic unrelated to the work presented here. M.J.M. is a paid speaker for Xarelto (Janssen Pharmaceuticals). All other authors report no potential conflicts.
ISSN:2328-8957
2328-8957
DOI:10.1093/ofid/ofad579